$TWST News
Last published 12h ago
- 12h agoTWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (“RSUs”) will be granted to 19 recently hired individuals, in each case as an inducement material to their acceptance of ...
- 2d agoTWSTTwist Bioscience to Present at Upcoming Investor ConferencesBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. Jefferies Global Healthcare Conference in London, ...
- 1w agoHYFTAMDNVDADHR+1Why the Next Edge in Antibody Discovery May Be What Labs RememberGlobeNewswireAUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - For most of the history of antibody discovery, the hard part was producing candidates. Generative models, high-throughput assays
- 1w agoTWSTTwist Bioscience Launches MRD Express with Rapid Turnaround TimeBusiness WireTurnaround time starting within one day Twist panel enables researchers to combine the sensitivity of tumor-informed MRD detection with the speed and simplicity of tumor-naïve MRD detection when developing their
- 2w agoTWSTTwist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening AntibodiesBusiness WireEnables high-throughput assessment of thousands of antibodies per day to support AI/ML-driven discovery workflows Turnaround time starting in as little as five days Twist Bioscience Corporation (NASDAQ:TWST), a
- 2w agoTWSTTwist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026Business WireCompany to host conference call at 8:00 AM ETTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth
- 1mo agoHYFTABCLLLYTWST+1AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireTowards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound...
- 1mo agoTWSTTwist Bioscience Joins Lilly TuneLab to Advance Antibody Drug DiscoveryBusiness WireAntibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today
- 1mo agoTWSTBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - TWIST BIOSCIENCE CORPEarnings Call TranscriptsPerfect. All right. Good afternoon, everyone. My name is Robbie Bamberger. I'm a senior research analyst here at Baird covering life sciences and diagnostics. Pleased to be joined by Emily LaProuste, who's the co-founder
- 1mo agoTWSTBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - TWIST BIOSCIENCE CORPEarnings Call TranscriptsPerfect. All right. Good afternoon, everyone. My name is Robbie Bamberger. I'm a senior research analyst here at Baird covering life sciences and diagnostics. Pleased to be joined by Emily LaProuste, who's the co-founder
- 2mo agoTWSTTwist Bioscience to Present at Baird 2026 Global Healthcare ConferenceBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience,
- 2mo agoHYFTTEMSDGRTWST+1AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030PR NewswireEquity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it....
- 3mo agoTWSTTwist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common StockBusiness WireTwist Bioscience Corporation (NASDAQ:TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock
- 3mo agoTWSTTwist Bioscience Announces Proposed Public Offering of $250.0 Million of Common StockBusiness WireTwist Bioscience Corporation (NASDAQ:TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common
- 3mo agoTWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireAs required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of
- 3mo agoTWSTTwist Bioscience Announces Fiscal 2026 Third Quarter Financial ResultsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the
- 3mo agoTWSTTwist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026Business WireCompany to host conference call at 8:00 AM ETTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third
- 5mo agoTWSTWILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE - TWIST BIOSCIENCE CORPEarnings Call TranscriptsAs for the management presentation for Twist Biosciences, my name is Matt LaRue. I cover the company here at William Blair. Pleased to be joined this morning by Dr. Emily Leproust, who's the CEO, and CFO Adam Lapanis, as
- 5mo agoTWSTTwist Bioscience to Present at William Blair 46th Annual Growth Stock ConferenceBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience
- 5mo agoTWSTTwist Bioscience Investor Day 2026TWIST BIOSCIENCE CORPEarnings Call TranscriptsI'm glad to welcome our CTO, Siwon Chen, who's going to tell us some of our strategy. Thank you, Siwan. Thank you. Hey, good morning, everyone. My name is Siwan Chen. I am the CTO on TwistaBio. I'm an oligochemist by tra
- 6mo agoTWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireAs required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity
- 6mo agoTWSTTwist Bioscience Fiscal 2026 Second Quarter Financial Results Conference CallTWIST BIOSCIENCE CORPEarnings Call TranscriptsWelcome to TWIST Biosciences' 2026 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
- 6mo agoTWSTTwist Bioscience Expands Clonal Genes Offering to Include Long and Complex SequencesBusiness WireSynthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products Complex synthesis capabilities to support
- 6mo agoTWSTTwist Bioscience Announces Fiscal 2026 Second Quarter Financial ResultsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the
- 6mo agoTWSTTwist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026Business WireCompany to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its
- 8mo agoTWSTTwist Bioscience to Present at Upcoming Investor ConferencesBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience,
- 8mo agoTWSTTwist Bioscience Conference Call to Discuss Bispecific Licensing AgreementTWIST BIOSCIENCE CORPEarnings Call TranscriptsGood day. Thank you for standing by. Welcome to TWIS Biosciences conference call to discuss the license agreement for the V-body by specific technology platform. At this time, all participants are in listen-only mode. Af
- 8mo agoTWSTTwist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing AgreementBusiness WireB-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput
- 9mo agoTWSTTwist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary EnzymesBusiness WireTwist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing
- 9mo agoTWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireAs required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity
- 9mo agoTWSTTwist Bioscience Fiscal 2026 First Quarter Financial Results Conference CallTWIST BIOSCIENCE CORPEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to TWIS Bioscience Fiscal 2026 First Quarter Financial Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's pre
- 9mo agoTWSTTwist Bioscience Announces Fiscal 2026 First Quarter Financial ResultsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the
- 10mo agoTWSTTwist Bioscience to Present at J.P. Morgan 2026 Healthcare ConferenceBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026
- 11mo agoTWSTTwist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics ResearchBusiness WireOffering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express Genes Enables nucleic acids therapeutics research, which can include
- 11mo agoTWSTKuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law FirmGlobeNewswireNEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ:TWST) breached their
- 12mo agoTWSTTwist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial ResultsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30,
- 1y agoTWSTKuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law FirmGlobeNewswireNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ:TWST) breached their
- 1y agoTWSTTwist Bioscience to Present at 7th Annual Wolfe Research Healthcare ConferenceBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist, will
- 1y agoTWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireAs required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that it has granted a total of
- 1y agoTWSTTwist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025Business WireCompany to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth
- 1y agoTWSTKuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ:...
- 1y agoTWSTTwist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ SystemBusiness Wire-- Launch of End-to-End Workflow for AVITI and AVITI24™ Enabling Sample to Sequencer in as Little as Five Hours -- -- Twist Gains Exclusive Access to the new, co-developed Trinity Freestyle™ Sequencing
- 1y agoTWSTTwist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein DesignBusiness WireStudy and red-teaming exercise led by Microsoft brought together consortium of scientific and industry experts Twist remains at the forefront of biosecurity innovation, demonstrating leadership in both policy
- 1y agoTWSTKuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ:...
- 1y agoTWSTTwist Bioscience to Present at Baird 2025 Global Healthcare ConferenceBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global
- 1y agoTWSTTwist Bioscience Collaborates with Synthetic Design LabBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). "With our high
- 1y agoTWSTTwist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS SolutionBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP)
- 1y agoTWSTTwist Bioscience Appoints Trynka Shineman Blake to Board of DirectorsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms.
- 1y agoTWSTTwist Bioscience Corporation (TWST) Q3 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTWSTTwist Bioscience Announces Fiscal 2025 Third Quarter Financial ResultsBusiness WireTwist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. "A strong balance sheet and